PriceTargets.com logo

Syros Pharmaceuticals - SYRS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.33
  • Forecasted Upside: 1,566.67%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.20 As of 12/20/2024 06:51 PM ET
▼ -0.0018 (-0.89%)

This chart shows the closing price for SYRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Syros Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYRS

Analyst Price Target is $3.33
▲ +1,566.67% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Syros Pharmaceuticals in the last 3 months. The average price target is $3.33, with a high forecast of $5.00 and a low forecast of $1.00. The average price target represents a 1,566.67% upside from the last price of $0.20.

This chart shows the closing price for SYRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Syros Pharmaceuticals. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024Brookline Capital ManagementReiterated RatingBuy ➝ Hold
11/13/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Perform
11/13/2024HC WainwrightReiterated RatingBuy ➝ Neutral$6.00 ➝ $1.00
11/13/2024TD CowenReiterated RatingBuy ➝ Hold
11/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
8/13/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$13.00 ➝ $5.00
8/13/2024HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $6.00
8/13/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$12.00 ➝ $4.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
6/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
4/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$13.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
10/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$11.00 ➝ $7.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
8/9/2023Piper SandlerLower Target$16.00 ➝ $11.00
5/11/2023JMP SecuritiesLower Target$16.00 ➝ $15.00
3/3/2023HC WainwrightReiterated RatingBuy$15.00
3/2/2023OppenheimerLower TargetOutperform$15.00 ➝ $13.00
1/5/2023Piper SandlerLower TargetOverweight$27.00 ➝ $20.00
12/12/2022JMP SecuritiesReiterated RatingBuy$16.00
11/15/2022JMP SecuritiesLower TargetMarket Outperform$40.00 ➝ $16.00
11/15/2022OppenheimerLower TargetOutperform$30.00 ➝ $15.00
11/15/2022HC WainwrightBoost TargetBuy$20.00
8/10/2022OppenheimerLower TargetOutperform$90.00 ➝ $30.00
7/12/2022HC WainwrightLower TargetBuy$100.00 ➝ $60.00
5/17/2022HC WainwrightLower TargetBuy$150.00 ➝ $100.00
5/16/2022Alliance Global PartnersLower TargetBuy$100.00
1/10/2022Piper SandlerLower Target$180.00 ➝ $100.00
11/8/2021HC WainwrightReiterated RatingBuy
9/23/2021Roth CapitalBoost TargetBuy$200.00 ➝ $230.00
9/21/2021JMP SecuritiesReiterated RatingBuy$200.00
8/6/2021JMP SecuritiesReiterated RatingBuy
6/24/2021HC WainwrightReiterated RatingBuy$150.00
5/30/2021JMP SecuritiesReiterated RatingBuy
3/5/2021Alliance Global PartnersLower Target$180.00 ➝ $140.00
11/10/2020Brookline Capital ManagementInitiated CoverageBuy$190.00
11/6/2020OppenheimerInitiated CoverageBuy$130.00
11/4/2020HC WainwrightUpgradeNeutral ➝ Buy$110.00 ➝ $150.00
10/26/2020Roth CapitalBoost TargetBuy$170.00 ➝ $200.00
10/25/2020OppenheimerInitiated CoverageBuy$130.00
9/22/2020Alliance Global PartnersInitiated CoverageBuy$180.00
8/10/2020HC WainwrightReiterated RatingHold$110.00
8/7/2020Piper SandlerBoost Target$140.00 ➝ $180.00
8/6/2020JMP SecuritiesBoost TargetOutperform$160.00 ➝ $200.00
6/1/2020OppenheimerInitiated CoverageBuy$110.00
5/29/2020Piper SandlerBoost TargetOverweight$120.00 ➝ $140.00
5/8/2020HC WainwrightReiterated RatingHold
5/7/2020OppenheimerReiterated RatingBuy$110.00
3/6/2020HC WainwrightReiterated RatingNeutral$100.00 ➝ $80.00
3/5/2020CowenReiterated RatingBuy
1/17/2020WedbushDowngradeOutperform ➝ Neutral$90.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.23 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Syros Pharmaceuticals logo
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.20
Low: $0.20
High: $0.22

50 Day Range

MA: $1.17
Low: $0.20
High: $3.23

52 Week Range

Now: $0.20
Low: $0.18
High: $8.17

Volume

2,836,203 shs

Average Volume

2,361,068 shs

Market Capitalization

$5.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Syros Pharmaceuticals?

The following sell-side analysts have issued research reports on Syros Pharmaceuticals in the last twelve months: Brookline Capital Management, HC Wainwright, JMP Securities, Piper Sandler, StockNews.com, and TD Cowen.
View the latest analyst ratings for SYRS.

What is the current price target for Syros Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Syros Pharmaceuticals in the last year. Their average twelve-month price target is $3.33, suggesting a possible upside of 1,566.7%. Piper Sandler has the highest price target set, predicting SYRS will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.00 for Syros Pharmaceuticals in the next year.
View the latest price targets for SYRS.

What is the current consensus analyst rating for Syros Pharmaceuticals?

Syros Pharmaceuticals currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SYRS, but not buy more shares or sell existing shares.
View the latest ratings for SYRS.

What other companies compete with Syros Pharmaceuticals?

Other companies that are similar to Syros Pharmaceuticals include Lakeshore Biopharma, MiNK Therapeutics, Calidi Biotherapeutics, Mannatech and Athira Pharma. Learn More about companies similar to Syros Pharmaceuticals.

How do I contact Syros Pharmaceuticals' investor relations team?

Syros Pharmaceuticals' physical mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 744-1340 and its investor relations email address is [email protected]. The official website for Syros Pharmaceuticals is www.syros.com. Learn More about contacing Syros Pharmaceuticals investor relations.